{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:54:46Z","timestamp":1794376486860,"version":"4.9.0"},"reference-count":37,"publisher":"Archives of Endocrinology and Metabolism","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,16]]},"DOI":"10.20945\/2359-3997000000549","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T07:05:12Z","timestamp":1668668712000},"page":"604-610","source":"Crossref","is-referenced-by-count":34,"title":["Hypoparathyroidism: update of guidelines from the 2022 International Task Force"],"prefix":"10.20945","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3801-9546","authenticated-orcid":false,"given":"Bart L.","family":"Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"key":"key20221117070508_B1","article-title":"Evaluation and management of hypoparathyroidism. Summary statement and guidelines from the 2nd Internation Workshop","author":"Khan","year":"2022","unstructured":"Khan AA, Bilezikian JP, Brandi ML, Clarke BL, Gittoes NJ, Pasieka JL, et al. Evaluation and management of hypoparathyroidism. Summary statement and guidelines from the 2nd Internation Workshop. J Bone Miner Res. 2022.","journal-title":"J Bone Miner Res"},{"key":"key20221117070508_B2","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.4675","article-title":"Epidemiology and financial burden of adult chronic hypoparathyroidism","author":"Bjornsdottir","year":"2022","unstructured":"Bjornsdottir S, Ing S, Mitchell DM, Sikjaer T, Underbjerg L, Hassan-Smith Z, et al. Epidemiology and financial burden of adult chronic hypoparathyroidism. J Bone Miner Res. 2022.","journal-title":"J Bone Miner Res"},{"key":"key20221117070508_B3","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.4714","article-title":"Etiology and pathophysiology of hypoparathyroidism: A narrative review","author":"Pasieka","year":"2022","unstructured":"Pasieka JL, Wentworth K, Yeo CT, Cremers S, Dempster DL, Fukumoto S, et al. Etiology and pathophysiology of hypoparathyroidism: A narrative review. J Bone Miner Res. 2022 Sept 26 [Epub ahead of print].","journal-title":"J Bone Miner Res"},{"key":"key20221117070508_B4","article-title":"J Bone Miner Res","author":"Mannstadt","year":"2022","unstructured":"Mannstadt M, Cianferotti L, Gafni RI, Giusti F, Kemp EH, Koch CA, et al. J Bone Miner Res. Hypoparathyroidism: Genetics and Diagnosis. 2022 Aug 4 [Epub ahead of print].","journal-title":"Hypoparathyroidism: Genetics and Diagnosis"},{"key":"key20221117070508_B5","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.4716","article-title":"Management of hypoparathyroidism","author":"Khan","year":"2022","unstructured":"Khan AA, Guyatt G, Ali DS, Bilezikian JP, Collins MT, Dandurand K, et al. Management of hypoparathyroidism. J Bone Miner Res. 2022 Sep 26 [Epub ahead of print].","journal-title":"J Bone Miner Res"},{"key":"key20221117070508_B6","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/jc.2015-3907","article-title":"Management of hypoparathyroidism: Summary statement and guidelines","volume":"101","author":"Brandi","year":"2016","unstructured":"Brandi ML, Bilezikian JP, Shoback DM, Bouillon R, Clarke BL, Thakker RV, et al. Management of hypoparathyroidism: Summary statement and guidelines. J Clin Endocrinol Metab. 2016;101:2273-83.","journal-title":"J Clin Endocrinol Metab"},{"key":"key20221117070508_B7","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.4687","article-title":"Methodology for the guidelines on evaluation and management of hypoparathyroidism and primary hyperparathyroidism","author":"Yao","year":"2022","unstructured":"Yao L, Guyatt G, Ye K, Bilezikian JP, Brandi ML, Clarke BL, et al. Methodology for the guidelines on evaluation and management of hypoparathyroidism and primary hyperparathyroidism. J Bone Miner Res. 2022.","journal-title":"J Bone Miner Res"},{"issue":"7","key":"key20221117070508_B8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Andrews","year":"2013","unstructured":"Andrews J, Guyatt GH, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719-25.","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"key20221117070508_B9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221173","article-title":"The effectiveness of parathyroid gland autotransplantation in preserving parathyroid function during thyroid surgery for thyroid neoplasms: A meta-analysis","volume":"14","author":"Wang","year":"2019","unstructured":"Wang B, Zhu CR, Liu H, Wu J. The effectiveness of parathyroid gland autotransplantation in preserving parathyroid function during thyroid surgery for thyroid neoplasms: A meta-analysis. PLoS One. 2019;14(8):e0221173.","journal-title":"PLoS One"},{"issue":"3","key":"key20221117070508_B10","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-18-0609","article-title":"Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus","volume":"180","author":"Khan","year":"2019","unstructured":"Khan AA, Koch CA, Van Uum S, Baillargeon JP, Bollerslev J, Brandi ML, et al. Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. Eur J Endocrinol. 2019;180(3):P1-22","journal-title":"Eur J Endocrinol"},{"key":"key20221117070508_B11","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.4673","article-title":"Complications and symptoms in patients with chronic hypoparathyroidism: a systematic review","author":"Yao","year":"2022","unstructured":"Yao L, Hui X, Li J, et al. Complications and symptoms in patients with chronic hypoparathyroidism: a systematic review. J Bone Miner Res. 2022.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"key20221117070508_B12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11154-020-09613-1","article-title":"Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review : Renal disease in chronic hypoparathyroidism","volume":"22","author":"Gosmanova","year":"2021","unstructured":"Gosmanova EO, Houillier P, Rejnmark L, Marelli C, Bilezikian JP. Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review : Renal disease in chronic hypoparathyroidism. Rev Endocr Metab Disord. 2021;22(2):297-316.","journal-title":"Rev Endocr Metab Disord"},{"issue":"10","key":"key20221117070508_B13","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40618-018-0857-5","article-title":"Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism","volume":"41","author":"Meola","year":"2018","unstructured":"Meola A, Vignali E, Matrone A, Cetani F, Marcocci C. Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism. J Endocrinol Invest. 2018;41(10):1221-6.","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"key20221117070508_B14","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1210\/jc.2012-1808","article-title":"Long-term follow-up of patients with hypoparathyroidism","volume":"97","author":"Mitchell","year":"2012","unstructured":"Mitchell DM, Regan S, Cooley MR, Lauter KB, Vrla MC, Becker CB, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012;97(12):4507-14.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"key20221117070508_B15","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/jbmr.3368","article-title":"Long-term complications in patients with hypoparathyroidism evaluated by biochemical findings: A case-control study","volume":"33","author":"Underbjerg","year":"2018","unstructured":"Underbjerg L, Sikjaer T, Rejnmark L. Long-term complications in patients with hypoparathyroidism evaluated by biochemical findings: A case-control study. J Bone Miner Res. 2018;33(5):822-31.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"key20221117070508_B16","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1007\/s12325-021-01658-1","article-title":"Risk of chronic kidney disease and estimated glomerular filtration rate decline in patients with chronic hypoparathyroidism: A retrospective cohort study","volume":"38","author":"Gosmanova","year":"2021","unstructured":"Gosmanova EO, Chen K, Rejnmark L, Mu F, Swallow E, Briggs A, et al. Risk of chronic kidney disease and estimated glomerular filtration rate decline in patients with chronic hypoparathyroidism: A retrospective cohort study. Adv Ther. 2021;38(4):1876-88.","journal-title":"Adv Ther"},{"issue":"1","key":"key20221117070508_B17","first-page":"251","article-title":"Vertebral fractures and bone mineral density in patients with idiopathic hypoparathyroidism on long-term follow-up","volume":"102","author":"Chawla","year":"2017","unstructured":"Chawla H, Saha S, Kandasamy D, Sharma R, Sreenivas V, Goswami R. Vertebral fractures and bone mineral density in patients with idiopathic hypoparathyroidism on long-term follow-up. J Clin Endocrinol Metab. 2017;102(1):251-8.","journal-title":"J Clin Endocrinol Metab"},{"key":"key20221117070508_B18","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.4698","article-title":"Initial assessment and monitoring of patients with chronic hypoparathyroidism: A systematic current practice survey","author":"Van Uum","year":"2022","unstructured":"Van Uum S, Shrayyef M, M\u2019Hiri I, et al. Initial assessment and monitoring of patients with chronic hypoparathyroidism: A systematic current practice survey. J Bone Miner Res. 2022.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"key20221117070508_B19","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-15-0628","article-title":"European Society of Endocrinology. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults","volume":"173","author":"Bollerslev","year":"2015","unstructured":"Bollerslev J, Rejnmark L, Marcocci C, Shoback DM, Sitges-Serra A, van Biesen W, et al.; European Society of Endocrinology. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015;173(2):G1-20.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"key20221117070508_B20","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1530\/EJE-21-1044","article-title":"2021 PARAT Working Group. European Expert Consensus on Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders","volume":"186","author":"Bollerslev","year":"2022","unstructured":"Bollerslev J, Rejnmark L, Zahn A, Heck A, Appelman-Dijkstra NM, Cardoso L, et al.; 2021 PARAT Working Group. European Expert Consensus on Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders. Eur J Endocrinol. 2022;186(2):R33-63.","journal-title":"Eur J Endocrinol"},{"key":"key20221117070508_B21","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.4676","article-title":"Parathyroid hormone therapy for managing chronic hypoparathyroidism: a systematic review and meta-analysis","author":"Yao","year":"2022","unstructured":"Yao L, Li J, Lin C, et al. Parathyroid hormone therapy for managing chronic hypoparathyroidism: a systematic review and meta-analysis. J Bone Miner Res. 2022.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"key20221117070508_B22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study","volume":"1","author":"Mannstadt","year":"2013","unstructured":"Mannstadt M, Clarke BL, Vokes T, Brandi ML, Ranganath L, Fraser WD, et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diab Endocrinol. 2013;1(4):275-83.","journal-title":"Lancet Diab Endocrinol"},{"issue":"11","key":"key20221117070508_B23","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1210\/jc.2019-00893","article-title":"Therapy of hypoparathyroidism with rhPTH(1-84): A prospective, 8-year investigation of efficacy and safety","volume":"104","author":"Tay","year":"2019","unstructured":"Tay YD, Tabacco G, Cusano NE, Williams J, Omeragic B, Majeed R, et al. Therapy of hypoparathyroidism with rhPTH(1-84): A prospective, 8-year investigation of efficacy and safety. J Clin Endocrinol Metab. 2019;104(11):5601-10.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"key20221117070508_B24","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Sikjaer","year":"2011","unstructured":"Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L. The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res. 2011;26(10):2358-70.","journal-title":"J Bone Miner Res"},{"issue":"11","key":"key20221117070508_B25","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1210\/jc.2019-01010","article-title":"Safety and efficacy of 5 years of treatment with recombinant human parathyroid hormone in adults with hypoparathyroidism","volume":"104","author":"Mannstadt","year":"2019","unstructured":"Mannstadt M, Clarke BL, Bilezikian JP, Bone H, Denham D, Levine MA, et al. Safety and efficacy of 5 years of treatment with recombinant human parathyroid hormone in adults with hypoparathyroidism. J Clin Endocrinol Metab. 2019;104(11):5136-47.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"key20221117070508_B26","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1210\/jc.2015-4135","article-title":"Therapy of hypoparathyroidism with PTH(1-84): A prospective six year investigation of efficacy and safety","volume":"101","author":"Rubin","year":"2016","unstructured":"Rubin MR, Cusano NE, Fan WW, Delgado Y, Zhang C, Costa AG, et al. Therapy of hypoparathyroidism with PTH(1-84): A prospective six year investigation of efficacy and safety. J Clin Endocrinol Metab. 2016;101(7):2742-50.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key20221117070508_B27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12020-016-1141-0","article-title":"Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study","volume":"55","author":"Clarke","year":"2017","unstructured":"Clarke BL, Vokes TJ, Bilezikian JP, Shoback DM, Lagast H, Mannstadt M. Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study. Endocrine. 2017;55(1):273-82.","journal-title":"Endocrine"},{"issue":"10","key":"key20221117070508_B28","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/jbmr.1964","article-title":"PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment","volume":"28","author":"Sikjaer","year":"2013","unstructured":"Sikjaer T, Amstrup AK, Rolighed L, Kjaer SG, Mosekilde L, Rejnmark L. PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment. J Bone Miner Res. 2013;28(10):2232-43.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"key20221117070508_B29","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1210\/clinem\/dgab577","article-title":"PaTH Forward: A randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism","volume":"107","author":"Khan","year":"2022","unstructured":"Khan A, Rejnmark L, Rubin M, Schwarz P, Vokes T, Clarke B, et al. PaTH Forward: A randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism. J Clin Endocrinol Metab. 2022;107(1):e372-85.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"key20221117070508_B30","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/jbmr.4016","article-title":"A Randomized Double-Blind Placebo-Controlled First-In-Human Phase 1 Trial of TransCon PTH in Healthy Adults","volume":"35","author":"Karpf","year":"2020","unstructured":"Karpf DB, Pihl S, Mourya S, Mortensen E, Kovoor E, Markova D, et al. A Randomized Double-Blind Placebo-Controlled First-In-Human Phase 1 Trial of TransCon PTH in Healthy Adults. J Bone Miner Res. 2020;35(8):1430-40.","journal-title":"J Bone Miner Res"},{"issue":"11","key":"key20221117070508_B31","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/jbmr.3824","article-title":"Design and preclinical development of TransCon PTH, an investigational sustained-release PTH replacement therapy for hypoparathyroidism","volume":"34","author":"Holten-Andersen","year":"2019","unstructured":"Holten-Andersen L, Pihl S, Rasmussen CE, Zettler J, Maitro G, Baron J, et al. Design and preclinical development of TransCon PTH, an investigational sustained-release PTH replacement therapy for hypoparathyroidism. J Bone Miner Res. 2019;34(11):2075-86.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"key20221117070508_B32","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1530\/EJE-18-0541","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: Hypoparathyroidism in pregnancy: review and evidence-based recommendations for management","volume":"180","author":"Khan","year":"2019","unstructured":"Khan AA, Clarke B, Rejnmark L, Brandi ML. MANAGEMENT OF ENDOCRINE DISEASE: Hypoparathyroidism in pregnancy: review and evidence-based recommendations for management. Eur J Endocrinol. 2019;180(2):R37-44.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"key20221117070508_B33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1152\/physrev.00027.2015","article-title":"Maternal mineral and bone metabolism during pregnancy, lactation, and post-weaning recovery","volume":"96","author":"Kovacs","year":"2016","unstructured":"Kovacs CS. Maternal mineral and bone metabolism during pregnancy, lactation, and post-weaning recovery. Physiol Rev. 2016;96(2):449-547.","journal-title":"Physiol Rev"},{"issue":"5","key":"key20221117070508_B34","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/00016349409006250","article-title":"Calcium homeostasis in normal pregnancy and puerperium. A longitudinal study","volume":"73","author":"Dahlman","year":"1994","unstructured":"Dahlman T, Sj\u00f6berg HE, Bucht E. Calcium homeostasis in normal pregnancy and puerperium. A longitudinal study. Acta Obstet Gynecol Scand. 1994;73(5):393-8.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"5 Pt 1","key":"key20221117070508_B35","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/0002-9378(91)90694-M","article-title":"Calcium-regulating hormones and osteocalcin levels during pregnancy: a longitudinal study","volume":"164","author":"Seki","year":"1991","unstructured":"Seki K, Makimura N, Mitsui C, Hirata J, Nagata I. Calcium-regulating hormones and osteocalcin levels during pregnancy: a longitudinal study. Am J Obstet Gynecol. 1991;164(5 Pt 1):1248-52.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"key20221117070508_B36","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1530\/eje.0.1370402","article-title":"Calcium-regulating hormones and parathyroid hormone-related peptide in normal human pregnancy and postpartum: a longitudinal study","volume":"137","author":"Ardawi","year":"1997","unstructured":"Ardawi MS, Nasrat HA, BA\u2019Aqueel HS. Calcium-regulating hormones and parathyroid hormone-related peptide in normal human pregnancy and postpartum: a longitudinal study. Eur J Endocrinol. 1997;137(4):402-9.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"key20221117070508_B37","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/cen.14212","article-title":"Changes in treatment needs of hypoparathyroidism during pregnancy and lactation: A case series","volume":"93","author":"Hartogsohn","year":"2020","unstructured":"Hartogsohn EAR, Khan AA, Kjaersulf LU, Sikjaer T, Hussain S, Rejnmark L. Changes in treatment needs of hypoparathyroidism during pregnancy and lactation: A case series. Clin Endocrinol (Oxf). 2020;93(3):261-8.","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T07:05:40Z","timestamp":1668668740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/hypoparathyroidism-update-of-guidelines-from-the-2022-international-task-force\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11,16]]}},"alternative-id":["10.20945\/2359-3997000000549"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000549","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}